A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.
Launched by NOVARTIS · Sep 22, 2006
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Must be able to complete a 1-week wash-out of current anti-diabetic medications
- • Cannot take any medications which may alter gastric motility except for cardiac medication at a stable dose
- • Blood glucose criteria must be met
- • BMI \<40
- Exclusion Criteria:
- • History of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes
- • Need for insulin within 3 months or patients on thiazolidinediones
- • Significant concommitant disease or complications of diabetes
- • Patients with any history of gastrointestinal surgery or positive gastrointestinal symptons
- • Abnormal liver function tests as defined by the protocol
- • Other protocol-defined inclusion/exclusion criteria may apply
About Novartis
Novartis is a global healthcare company based in Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovative pharmaceuticals, Novartis engages in the research, development, and commercialization of a wide range of therapies across various therapeutic areas, including oncology, cardiology, immunology, and neuroscience. The company is committed to advancing clinical research through rigorous trials that prioritize patient safety and efficacy, aiming to deliver groundbreaking treatments and solutions that address unmet medical needs worldwide. Novartis's commitment to innovation and collaboration positions it at the forefront of the biopharmaceutical industry, driving advancements that enhance patient care and health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, , Germany
Patients applied
Trial Officials
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials